title: Ligands to the platelet fibrinogen receptor glycoprotein IIb-IIIa do not affect agonist-induced second messengers Ca2+ or cyclic AMP.
abstract: Previous studies have suggested that the platelet glycoprotein complex GPIIb-IIIa, which is the putative fibrinogen receptor, regulates Ca2+ influx into platelets, possibly operating as a Ca2+ channel. We have used RGD-peptides (peptides containing the sequence Arg-Gly-Asp; disintegrins), isolated from snake venoms, that have a high affinity and specificity for the fibrinogen-binding site of GPIIb-IIIa to address the question of whether blocking this site inhibits Ca2+ movement from the extracellular medium to the cytosol. Using fura-2-loaded human platelets, we found that neither disintegrins nor a monoclonal antibody (M148) to the GPIIb-IIIa complex altered the level of cytosolic Ca2+ obtained when the cells were stimulated with various agonists in the presence of either nominal or 1 mM extracellular Ca2+. In the presence of Mn2+, an ion that quenches fura-2 fluorescence, fura-2-loaded platelets were stimulated with thrombin or ADP. Neither disintegrins nor the monoclonal antibody altered the kinetics or the amount of quenching of fura-2 fluorescence by Mn2+. These data indicate that the binding of ligands to the fibrinogen receptor is not associated with an inhibition of Ca2+ movement through a receptor-operated channel. Furthermore, the disintegrins have no effect on platelet cyclic AMP metabolism in either the presence or the absence of phosphodiesterase inhibitors.
authors.affiliation: Department of Physiology, Temple University Medical School, Philadelphia, PA 19140.
authors.forename: J A
authors.initials: JA
authors.lastname: Williams
authors.forename: B
authors.initials: B
authors.lastname: Ashby
authors.forename: J L
authors.initials: JL
authors.lastname: Daniel
mesh_terms: D000911:Antibodies, Monoclonal; D001792:Blood Platelets / Q000502:physiology*; D002118:Calcium / Q000502:physiology; D000242:Cyclic AMP / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D008345:Manganese / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010980:Platelet Membrane Glycoproteins / Q000502:physiology*; D015398:Signal Transduction; D012910:Snake Venoms; D014757:Viper Venoms / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D008024:Ligands; D010455:Peptides; D010980:Platelet Membrane Glycoproteins; D012910:Snake Venoms; D014757:Viper Venoms; C064594:elegantin; C064595:albolabrin; D008345:Manganese; D000242:Cyclic AMP; D002118:Calcium